On Monday, I wrote on the importance of being prepared for an emergency. I did so thinking of Hurricane Irene. We're expecting some contact with Irene as it rolls up the East Coast, so I thought it was a good time to remind everyone of the general value of emergency preparedness.
Most Recent Posts
"Horrifying," that's how one of my colleagues here described this item detailing the growing toll of the diabetes pandemic. The bottom line? One in four adults in the U.S. now has diabetes, a number that has doubled in just the past 30 years.
Hurricane Irene came ashore over Puerto Rico this weekend. It could potentially affect parts of the U.S. mainland including, Florida, Georgia, and South Carolina. This is a good time to remind everyone whether living in these states or not how it important it is to plan for emergencies.
Biopharmaceutical research companies are dedicated to bringing medicines to the patients we serve. That's why helping to ensure reliable patient access to these life-saving medicines is a key goal of our companies. Many drug shortages involve generic drugs, according to FDA.
First, saw this interesting report: cures for new diseases come from old medicines. Now, coming from an organization that represents innovative medicine makers, it may seem strange to highlight that older, probably generic medicines may have new applications. But what strikes me, however, is that it is really a story about science, innovation and the power of ideas.
It likely won't have clinical implications - in other words, it won't replace the current gold standard for detecting cancer - but this study (covered by CNN) in the European Respiratory Journal found that dogs may be able to identify lung cancer by smell.
It just proves that dogs are good for more than rescuing Timmy from trouble down at the Old Mill.
This is a "they missed the real story" story. Yesterday, Phama Times ran a story on the effort of a small group of Congressmen to keep biosimilars out of any Trans-Pacific trade deal. The story was factual so far as it goes and, certainly, it did note PhRMA's long-standing position on biosimilars data protection:
Until yesterday, biopharmaceutical research companies were allowed to disable comments from users on certain Facebook pages. This helped companies ensure that those pages were sources of accurate information, though it meant they were removing some ability to engage the public in a dialogue.
Austin Frakt over at the Incidental Economist weighs in on the recent JAMA study on the value of the Medicare Part D program. The JAMA study found that Part D saves Medicare about $1,200 per year in hospital, nursing home and other costs for each senior who previously lacked comprehensive prescription drug coverage.